These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17720513)

  • 1. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe.
    Macdougall IC
    Am J Kidney Dis; 2007 Sep; 50(3):358-61. PubMed ID: 17720513
    [No Abstract]   [Full Text] [Related]  

  • 2. Dialysis facility ownership and epoetin dosing in hemodialysis patients: an overview.
    Weiner DE; Levey AS
    Am J Kidney Dis; 2007 Sep; 50(3):349-53. PubMed ID: 17720511
    [No Abstract]   [Full Text] [Related]  

  • 3. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective.
    Lazarus JM; Hakim RM
    Am J Kidney Dis; 2007 Sep; 50(3):366-70. PubMed ID: 17720515
    [No Abstract]   [Full Text] [Related]  

  • 4. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective.
    Cohen JT; Neumann PJ
    Am J Kidney Dis; 2007 Sep; 50(3):362-5. PubMed ID: 17720514
    [No Abstract]   [Full Text] [Related]  

  • 5. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a US physician perspective.
    Kasiske BL
    Am J Kidney Dis; 2007 Sep; 50(3):354-7. PubMed ID: 17720512
    [No Abstract]   [Full Text] [Related]  

  • 6. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Hernán MA
    Am J Kidney Dis; 2007 Oct; 50(4):538-41. PubMed ID: 17900452
    [No Abstract]   [Full Text] [Related]  

  • 8. Epoetin dosing and dialysis facility ownership.
    Kliger AS; Nissenson AR
    JAMA; 2007 Aug; 298(8):861-2; author reply 862-3. PubMed ID: 17712067
    [No Abstract]   [Full Text] [Related]  

  • 9. Epoetin dosing and dialysis facility ownership.
    Regidor DL; Kalantar-Zadeh K; Kovesdy CP
    JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
    Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
    Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
    Holloway M
    Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
    Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of epoetin in chronic renal failure.
    Coyne DW
    JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic kidney disease, anemia, and epoetin.
    Roger SD
    N Engl J Med; 2007 Mar; 356(9):958; author reply 958-9. PubMed ID: 17338047
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic kidney disease, anemia, and epoetin.
    Mikhail A; Goldsmith D
    N Engl J Med; 2007 Mar; 356(9):956-7; author reply 958-9. PubMed ID: 17338045
    [No Abstract]   [Full Text] [Related]  

  • 17. Epoetin alfa in the critically ill: What dose? Which route?
    Napolitano LM
    Crit Care Med; 2009 Apr; 37(4):1501-3. PubMed ID: 19318838
    [No Abstract]   [Full Text] [Related]  

  • 18. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV; Robinson K; Singh AK
    Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss.
    Arroliga AC; Guntupalli KK; Beaver JS; Langholff W; Marino K; Kelly K
    Crit Care Med; 2009 Apr; 37(4):1299-307. PubMed ID: 19242343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.